Literature DB >> 19377320

Program design and long-run costs of a national catastrophic drug insurance plan.

Hai Zhong1.   

Abstract

There are strong arguments that national catastrophic drug insurance should be established in Canada with assistance from the federal government. The author of this paper projects the long-run program costs for two proposals for such a program: that of the Kirby Committee and that of the Romanow Commission. He concludes that both the annual program costs to the federal government and the share of the federal government on total prescription drug expenditures in Canada would increase dramatically under either program. Although the Kirby-style program requires less initial expenditure by the federal government than does the Romanow-style program, because of their different designs, over time the Kirby-style program would become more expensive. Moreover, the Kirby-style program would be more sensitive to the growth rate of prescription drug expenditure. The choices relating to the program threshold and federal cost-sharing rate have far-reaching influences on the long-run costs to the federal government.
Copyright © 2008 Longwoods Publishing.

Year:  2008        PMID: 19377320      PMCID: PMC2645158     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  8 in total

1.  Cost-sharing and pharmaceutical utilisation and expenditure in Russia.

Authors:  A Street; A Jones; A Furuta
Journal:  J Health Econ       Date:  1999-08       Impact factor: 3.883

2.  Do new prescription drugs pay for themselves? The case of second-generation antipsychotics.

Authors:  Mark Duggan
Journal:  J Health Econ       Date:  2005-01       Impact factor: 3.883

3.  Booming prescription drug expenditure: a population-based analysis of age dynamics.

Authors:  Steven G Morgan
Journal:  Med Care       Date:  2005-10       Impact factor: 2.983

4.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

Authors:  R Tamblyn; R Laprise; J A Hanley; M Abrahamowicz; S Scott; N Mayo; J Hurley; R Grad; E Latimer; R Perreault; P McLeod; A Huang; P Larochelle; L Mallet
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

5.  The demand for prescription drugs as a function of cost-sharing.

Authors:  A Leibowitz; W G Manning; J P Newhouse
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

6.  Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

Authors:  S B Soumerai; T J McLaughlin; D Ross-Degnan; C S Casteris; P Bollini
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

7.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

Authors:  S B Soumerai; D Ross-Degnan; J Avorn; T j McLaughlin; I Choodnovskiy
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

8.  Health insurance and the demand for medical care: evidence from a randomized experiment.

Authors:  W G Manning; J P Newhouse; N Duan; E B Keeler; A Leibowitz; M S Marquis
Journal:  Am Econ Rev       Date:  1987-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.